CoChat

The Cooperative Functions of the EBNA3 Proteins Are Central to EBV Persistence and Latency

Styles, Christine, Paschos, Kostas, White, Robert, Farrell, Paul · 2018 · Pathogens
Cited by 41

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The Epstein–Barr nuclear antigen 3 (EBNA3) family of proteins, comprising EBNA3A, EBNA3B, and EBNA3C, play pivotal roles in the asymptomatic persistence and life-long latency of Epstein–Barr virus (EBV) in the worldwide human population. EBNA3-mediated transcriptional reprogramming of numerous host cell genes promotes in vitro B cell transformation and EBV persistence in vivo. Despite structural and sequence similarities, and evidence of substantial cooperative activity between the EBNA3 proteins, they perform quite different, often opposing functions. Both EBNA3A and EBNA3C are involved in the repression of important tumour suppressive pathways and are considered oncogenic. In contrast, EBNA3B exhibits tumour suppressive functions. This review focuses on how the EBNA3 proteins achieve the delicate balance required to support EBV persistence and latency, with emphasis on the contribution of the Allday laboratory to the field of EBNA3 biology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pathogens7010031

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 80

  1. Klein, 2002, Perspectives in studies of human tumor viruses, Front. Biosci., 7, d268, 10.2741/klein · doi:10.2741/klein
  2. Young, 2004, Epstein-Barr virus: 40 years on, Nat. Rev. Cancer, 4, 757, 10.1038/nrc1452 · DOI · Paper page
  3. Roughan, 2009, The intersection of Epstein-Barr virus with the germinal center, J. Virol., 83, 3968, 10.1128/JVI.02609-08 · doi:10.1128/jvi.02609-08
  4. Yenamandra, 2009, Comparative analysis of the Epstein-Barr virus encoded nuclear proteins of EBNA-3 family, Comput. Biol. Med., 39, 1036, 10.1016/j.compbiomed.2009.08.006 · DOI
  5. Kerdiles, 1994, The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter, Virology, 205, 596, 10.1006/viro.1994.1687 · doi:10.1006/viro.1994.1687
  6. Touitou, 2005, Epstein-Barr virus EBNA3 proteins bind to the c8/alpha7 subunit of the 20s proteasome and are degraded by 20s proteasomes in vitro, but are very stable in latently infected B cells, J. Gen. Virol., 86, 1269, 10.1099/vir.0.80763-0 · DOI
  7. Davies, 2010, Cellular factors associated with latency and spontaneous Epstein-Barr virus reactivation in B-lymphoblastoid cell lines, Virology, 400, 53, 10.1016/j.virol.2010.01.002 · DOI
  8. White, R.E., Groves, I.J., Turro, E., Yee, J., Kremmer, E., and Allday, M.J. (2010). Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS ONE, 5. · DOI
  9. Anderton, 2008, Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor BIM: Clues to the pathogenesis of Burkitt’s lymphoma, Oncogene, 27, 421, 10.1038/sj.onc.1210668 · DOI · Paper page
  10. Skalska, L., White, R.E., Franz, M., Ruhmann, M., and Allday, M.J. (2010). Epigenetic repression of p16(INK4a) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog., 6. · DOI · Paper page
  11. Maruo, 2006, Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells, Proc. Natl. Acad. Sci. USA, 103, 19500, 10.1073/pnas.0604919104 · DOI · Paper page
  12. Bazot, Q., Paschos, K., Skalska, L., Kalchschmidt, J.S., Parker, G.A., and Allday, M.J. (2015). Epstein-Barr virus proteins EBNA3A and EBNA3C together induce expression of the oncogenic microRNA cluster miR-221/miR-222 and ablate expression of its target p57KIP2. PLoS Pathog., 11. · DOI
  13. Styles, C.T., Bazot, Q., Parker, G.A., White, R.E., Paschos, K., and Allday, M.J. (2017). EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency. PLoS Biol., 15. · DOI · Paper page
  14. Maruo, 2003, Epstein-Barr virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth, J. Virol., 77, 10437, 10.1128/JVI.77.19.10437-10447.2003 · doi:10.1128/jvi.77.19.10437-10447.2003
  15. Paschos, 2012, BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV, Nucleic Acids Res., 40, 7233, 10.1093/nar/gks391 · DOI
  16. Jiang, 2014, Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits SIN3A to repress CDKN2A, Proc. Natl. Acad. Sci. USA, 111, 421, 10.1073/pnas.1321704111 · DOI
  17. Schmidt, 2015, Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes, Proc. Natl. Acad. Sci. USA, 112, 554, 10.1073/pnas.1422580112 · DOI
  18. Paschos, 2016, Core binding factor (CBF) is required for Epstein-Barr virus EBNA3 proteins to regulate target gene expression, Nucl. Acids Res., 45, 2368, 10.1093/nar/gkw1167 · DOI
  19. Parker, 1996, Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7, Oncogene, 13, 2541
  20. Allday, 2015, The EBNA3 family: Two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells, Curr. Top. Microbiol. Immunol., 391, 61
  21. Lee, 1999, Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus, J. Virol., 73, 2974, 10.1128/JVI.73.4.2974-2982.1999 · DOI
  22. Cohen, 1989, Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation, Proc. Natl. Acad. Sci. USA, 86, 9558, 10.1073/pnas.86.23.9558 · DOI · Paper page
  23. Tomkinson, 1993, Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation, J. Virol., 67, 2014, 10.1128/jvi.67.4.2014-2025.1993 · DOI · Paper page
  24. Kaye, 1993, Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation, Proc. Natl. Acad. Sci. USA, 90, 9150, 10.1073/pnas.90.19.9150 · DOI · Paper page
  25. Mannick, 1991, The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation, J. Virol., 65, 6826, 10.1128/jvi.65.12.6826-6837.1991 · DOI · Paper page
  26. Hertle, M.L., Popp, C., Petermann, S., Maier, S., Kremmer, E., Lang, R., Mages, J., and Kempkes, B. (2009). Differential gene expression patterns of EBV infected EBNA-3A positive and negative human b lymphocytes. PLoS Pathog., 5. · DOI
  27. White, 2012, EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors, J. Clin. Invest., 122, 1487, 10.1172/JCI58092 · DOI · Paper page
  28. Robertson, 1996, The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa), J. Virol., 70, 3068, 10.1128/jvi.70.5.3068-3074.1996 · doi:10.1128/jvi.70.5.3068-3074.1996
  29. Robertson, 1995, Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa, J. Virol., 69, 3108, 10.1128/jvi.69.5.3108-3116.1995 · DOI · Paper page
  30. Kalchschmidt, J.S., Gillman, A.C., Paschos, K., Bazot, Q., Kempkes, B., and Allday, M.J. (2016). EBNA3C directs recruitment of RBPJ (CBF1) to chromatin during the process of gene repression in EBV infected B cells. PLoS Pathog., 12. · DOI
  31. Zhao, 1996, A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of J kappa, J. Virol., 70, 4228, 10.1128/jvi.70.7.4228-4236.1996 · DOI
  32. West, 2017, Chromatin reorganisation in Epstein-Barr virus-infected cells and its role in cancer development, Curr. Opin. Virol., 26, 149, 10.1016/j.coviro.2017.08.004 · DOI
  33. Johannsen, 1996, EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes, J. Virol., 70, 4179, 10.1128/jvi.70.6.4179-4183.1996 · doi:10.1128/jvi.70.6.4179-4183.1996
  34. Radkov, 1997, Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21, J. Virol., 71, 8552, 10.1128/jvi.71.11.8552-8562.1997 · DOI
  35. Maruo, 2005, Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: Transcriptional regulation through RBP-jkappa/CBF1 is critical, J. Virol., 79, 10171, 10.1128/JVI.79.16.10171-10179.2005 · DOI
  36. Maruo, 2009, Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth, Proc. Natl. Acad. Sci. USA, 106, 4419, 10.1073/pnas.0813134106 · doi:10.1073/pnas.0813134106
  37. Lee, 2009, Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: Interaction with RBP-Jkappa regulates TCL1, J. Virol., 83, 12368, 10.1128/JVI.01403-09 · DOI
  38. McClellan, M.J., Wood, C.D., Ojeniyi, O., Cooper, T.J., Kanhere, A., Arvey, A., Webb, H.M., Palermo, R.D., Harth-Hertle, M.L., and Kempkes, B. (2013). Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming. PLoS Pathog., 9. · DOI
  39. Wang, 2015, Epstein-Barr virus nuclear antigen 3 (EBNA3) proteins regulate EBNA2 binding to distinct RBPJ genomic sites, J. Virol., 90, 2906, 10.1128/JVI.02737-15 · DOI
  40. Harth-Hertle, M.L., Scholz, B.A., Erhard, F., Glaser, L.V., Dölken, L., Zimmer, R., and Kempkes, B. (2013). Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9. PLoS Pathog., 9. · DOI
  41. Wood, C.D., Veenstra, H., Khasnis, S., Gunnell, A., Webb, H.M., Shannon-Lowe, C., Andrews, S., Osborne, C.S., and West, M.J. (2016). MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs. eLife, 5. · DOI · Paper page
  42. Skalska, L., White, R.E., Parker, G.A., Turro, E., Sinclair, A.J., Paschos, K., and Allday, M.J. (2013). Induction of p16(INK4a) is the major Barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog., 9. · DOI
  43. Hickabottom, 2002, Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP), J. Biol. Chem., 277, 47197, 10.1074/jbc.M208116200 · DOI
  44. Knight, 2003, Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSIN3A and NCoR in human B-cell lines, J. Virol., 77, 4261, 10.1128/JVI.77.7.4261-4272.2003 · DOI
  45. Radkov, 1999, Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription, J. Virol., 73, 5688, 10.1128/JVI.73.7.5688-5697.1999 · DOI
  46. Touitou, 2001, Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C, J. Virol., 75, 7749, 10.1128/JVI.75.16.7749-7755.2001 · DOI
  47. Cotter, 2000, Modulation of histone acetyltransferase activity through interaction of Epstein-Barr nuclear antigen 3C with prothymosin alpha, Mol. Cell. Biol., 20, 5722, 10.1128/MCB.20.15.5722-5735.2000 · DOI
  48. Kalchschmidt, 2016, Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells, J. Exp. Med., 213, 921, 10.1084/jem.20160120 · DOI
  49. Frangini, 2013, The aurora B kinase and the polycomb protein Ring1b combine to regulate active promoters in quiescent lymphocytes, Mol. Cell, 51, 647, 10.1016/j.molcel.2013.08.022 · DOI
  50. McClellan, 2012, Downregulation of integrin receptor-signaling genes by Epstein-Barr virus EBNA 3C via promoter-proximal and -distal binding elements, J. Virol., 86, 5165, 10.1128/JVI.07161-11 · doi:10.1128/jvi.07161-11
  51. Bazot, Q., Paschos, K., and Allday, M.J. (2018). Epstein-Barr virus latent protein EBNA3A directly targets and silences the kinase STK39 in B cells infected by EBV. J. Virol. · DOI
  52. Allday, 2013, EBV finds a polycomb-mediated, epigenetic solution to the problem of oncogenic stress responses triggered by infection, Front. Genet., 4, 212, 10.3389/fgene.2013.00212 · DOI
  53. Maruo, 2011, Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4a and p14ARF expression, Proc. Natl. Acad. Sci. USA, 108, 1919, 10.1073/pnas.1019599108 · DOI
  54. Chinnadurai, 2009, The transcriptional corepressor CtBP: A foe of multiple tumor suppressors, Cancer Res., 69, 731, 10.1158/0008-5472.CAN-08-3349 · DOI · Paper page
  55. Bazot, 2014, Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1, Nucleic Acids Res., 42, 9700, 10.1093/nar/gku697 · DOI
  56. Jiang, 2017, The Epstein-Barr virus regulome in lymphoblastoid cells, Cell Host Microbe, 22, 561, 10.1016/j.chom.2017.09.001 · DOI
  57. Banerjee, S., Lu, J., Cai, Q., Sun, Z., Jha, H.C., and Robertson, E.S. (2014). EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation. PLoS Pathog., 10. · DOI
  58. Tursiella, M.L., Bowman, E.R., Wanzeck, K.C., Throm, R.E., Liao, J., Zhu, J., and Sample, C.E. (2014). Epstein-Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. PLoS Pathog., 10. · DOI
  59. Strasser, 2005, The role of BH3-only proteins in the immune system, Nat. Rev. Immunol., 5, 189, 10.1038/nri1568 · DOI · Paper page
  60. Fischer, 2007, Proapoptotic BH3-only protein BIM is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells, Blood, 110, 3978, 10.1182/blood-2007-05-091306 · DOI · Paper page
  61. Dang, 2005, The great MYC escape in tumorigenesis, Cancer Cell, 8, 177, 10.1016/j.ccr.2005.08.005 · DOI
  62. Egle, 2004, BIM is a suppressor of MYC-induced mouse B cell leukemia, Proc. Natl. Acad. Sci. USA, 101, 6164, 10.1073/pnas.0401471101 · DOI · Paper page
  63. Paschos, K., Smith, P., Anderton, E., Middeldorp, J.M., White, R.E., and Allday, M.J. (2009). Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene BIM. PLoS Pathog., 5. · DOI · Paper page
  64. Allday, 2008, The curious case of the tumour virus: 50 years of Burkitt’s lymphoma, Nat. Rev. Microbiol., 6, 913, 10.1038/nrmicro2015 · DOI · Paper page
  65. Nikitin, 2010, An ATM/CHK2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells, Cell Host Microbe, 8, 510, 10.1016/j.chom.2010.11.004 · DOI · Paper page
  66. Saha, 2009, Epstein-Barr virus nuclear antigen 3C augments MDM2-mediated p53 ubiquitination and degradation by deubiquitinating MDM2, J. Virol., 83, 4652, 10.1128/JVI.02408-08 · DOI
  67. Yi, 2009, Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities, Virology, 388, 236, 10.1016/j.virol.2009.03.027 · DOI
  68. Jha, 2014, Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression, J. Virol., 88, 3776, 10.1128/JVI.03568-13 · DOI
  69. Knight, 2005, Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase, Proc. Natl. Acad. Sci. USA, 102, 18562, 10.1073/pnas.0503886102 · DOI · Paper page
  70. Saha, A., Lu, J., Morizur, L., Upadhyay, S.K., Aj, M.P., and Robertson, E.S. (2012). E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog., 8. · DOI
  71. Knight, 2004, Epstein-Barr virus nuclear antigen 3C regulates cyclin a/p27 complexes and enhances cyclin a-dependent kinase activity, J. Virol., 78, 1981, 10.1128/JVI.78.4.1981-1991.2004 · DOI
  72. Knight, 2005, Scfskp2 complex targeted by Epstein-Barr virus essential nuclear antigen, Mol. Cell. Biol., 25, 1749, 10.1128/MCB.25.5.1749-1763.2005 · DOI
  73. Bajaj, 2008, Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-MYC oncoprotein, J. Virol., 82, 4082, 10.1128/JVI.02500-07 · DOI
  74. Tomkinson, 1992, Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro, J. Virol., 66, 2893, 10.1128/jvi.66.5.2893-2903.1992 · doi:10.1128/jvi.66.5.2893-2903.1992
  75. Gagrica, 2012, Contrasting behavior of the p18INK4c and p16INK4a tumor suppressors in both replicative and oncogene-induced senescence, Cancer Res., 72, 165, 10.1158/0008-5472.CAN-11-2552 · DOI
  76. Morse, 1997, Induction of cell cycle arrest and B cell terminal differentiation by cdk inhibitor p18(INK4c) and il-6, Immunity, 6, 47, 10.1016/S1074-7613(00)80241-1 · DOI · Paper page
  77. Tourigny, 2002, Cdk inhibitor p18(INK4c) is required for the generation of functional plasma cells, Immunity, 17, 179, 10.1016/S1074-7613(02)00364-3 · DOI
  78. Boi, 2015, PRDM1/BLIMP1: A tumor suppressor gene in B and T cell lymphomas, Leuk. Lymphoma, 56, 1223, 10.3109/10428194.2014.953155 · DOI
  79. Mandelbaum, 2010, BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma, Cancer Cell, 18, 568, 10.1016/j.ccr.2010.10.030 · DOI · Paper page
  80. Minnich, 2016, Multifunctional role of the transcription factor BLIMP-1 in coordinating plasma cell differentiation, Nat. Immunol., 17, 331, 10.1038/ni.3349 · DOI · Paper page

Cited by

See all 41

Metadata

Authors
Styles, C., Paschos, K., White, R., & Farrell, P.
Affiliations
Molecular Virology, Department of Medicine, Imperial College London, London W2 1PG, UK
Venue
Pathogens
Publisher
MDPI AG
Published
2018-03-17
Volume
7
Issue
1
Pages
31
ISSN
2076-0817
Cited by
41
References
3
Language
en
Funders
  • Wellcome Trust (099273/Z/12/Z)
  • MRC (G01362)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.